Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Maximilian Schinke, Inga Promny, MD, Stefanie Hieke, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, PhD, Milena Pantic, PhD, Justus Duyster, MD, Ralph Wäsch, MD PhD, Martin Schuhmacher, PhD, Monika Engelhardt, MD

Blood (2015) 126 (23): 2091.

https://doi.org/10.1182/blood.V126.23.2091.2091

Published: 2015

Journal Articles

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Benjamin Kobitzsch, Nicola Gökbuget, MD, Stefan Schwartz, MD, Richard Reinhardt, PhD, Monika Brueggemann, Andreas Viardot, MD, Ralph Wäsch, MD PhD, Michael Starck, MD, Eckhard Thiel, MD, Dieter Hoelzer, MD, Thomas Burmeister, MD

Blood (2015) 126 (23): 2617.

https://doi.org/10.1182/blood.V126.23.2617.2617

Published: 2015

Journal Articles

Self-Renewal and Differentiation in Hematopoietic Stem and Progenitor Cells Is Controlled By the APC/C Coactivator Cdh1

Daniel Ewerth, Stefanie Kreutmair, Birgit Kügelgen, Dagmar Wider, Julia Felthaus, Julia Schüler, DVM, PhD, Andrea Schmidts, Justus Duyster, MD PhD, Anna Lena Illert, Monika Engelhardt, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 2370.

https://doi.org/10.1182/blood.V126.23.2370.2370

Published: 2015

Journal Articles

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Alexander Keller, MD, Johannes M. Waldschmidt, MD, Dagmar Wider, Dorothee Jakobs, Mandy Möller, Heike Reinhardt, Milena Pantic, PhD, Olga Grishina, MD, Gabriele Ihorst, PhD, Annette M May, MD, Anna Frey, MD, Ulrike Kohlweyer, PhD, Justus Duyster, MD PhD, Manfred Jung, PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 4260.

https://doi.org/10.1182/blood.V126.23.4260.4260

Published: 2015

Journal Articles

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Andreas R. Thomsen, MD, Claudius Klein, Christine Aldrian, Martin Kortuem, MD, Marie Follo, PhD, Julia Schüler, DVM, PhD, Justus Duyster, MD PhD, Monika Engelhardt, MD PhD, Ralph Wäsch, MD PhD

Blood (2015) 126 (23): 1822.

https://doi.org/10.1182/blood.V126.23.1822.1822

Published: 2015

NARROW

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Self-Renewal and Differentiation in Hematopoietic Stem and Progenitor Cells Is Controlled By the APC/C Coactivator Cdh1

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Non-Functional ("haploinsufficient"), but Not Dominant Negative Clonal IKZF1 Deletions Confer an Adverse Prognosis in Adult BCR-ABL -Negative Acute Lymphoblastic Leukemia

Self-Renewal and Differentiation in Hematopoietic Stem and Progenitor Cells Is Controlled By the APC/C Coactivator Cdh1

Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD)

Mimicking the Myeloma Niche: A 3D Bone-Derived Co-Culture System to Selectively Assess Bystander BMSCs and to Perform High-Throughput Drug Screening in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only